We would like to inform our sponsors about our new capabilities and latest accomplishments:

• The recent FDA pre-approval inspection audit of our Phase II clinical study site and office facilities in Moscow, Russia, was flawless and resulted in no FDA 483 remarks for the sponsor
• Our biomarker facility in Heidelberg, Germany, was GLP qualified in February 2009
• Several first-in-human studies with biologicals have been performed in our hospital-based ward in Düsseldorf, Germany, which has just been upgraded from six to 12 beds
• Our expertise in the conduct of ethnic bridging studies has been expanded by the
  addition of more Asian and African ethnicities, and a broader range of study objectives
• We recently created a pharmaco-imaging centre with three university experts in the region of Neuss, Germany. By adding these high-tech imaging technologies to the FOCUS exploratory clinical expertise, we hope to offer our sponsors more
  opportunities to perform state-of-the-art studies

Contact FOCUS Clinical Drug Development for more information about any of these news items.